Cantor Fitzgerald analyst Pete Stavropoulos reinstates coverage on Pliant Therapeutics (NASDAQ: PLRX) with a Neutral rating.The analyst comments: "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE